Difference between revisions of "Template:SPCaripiprazoleLA"

Revision as of 12:29, 20 February 2025

More information you'll find in the summary of product characteristics (SPC) of aripiprazole depot injection. ^[1]
Aripiprazol Abilify Maintena is a prolonged release suspension for injection and is available in 400mg (once a month) and 960mg (once every two months) preparations. A reduced dose of 75% (300mg and 720mg respectively) can be needed when experiencing side effects.

Revision as of 12:22, 20 February 2025 (view source) Casper (talk \| contribs) ← Older edit		Revision as of 12:29, 20 February 2025 (view source) Casper (talk \| contribs) Newer edit →
Line 1:		Line 1:
	* More information you'll find in the summary of product characteristics (SPC) of aripiprazole depot injection. <ref>https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena SPC of the European Medicines Agency on aripiprazole depot</ref>		* More information you'll find in the summary of product characteristics (SPC) of aripiprazole depot injection. <ref>https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena SPC of the European Medicines Agency on aripiprazole depot</ref>
−	* Aripiprazol Abilify Maintena is a prolonged release suspension for injection and is available in 400mg and 960mg preparations. ~~It is possible to administer a~~ reduced ~~dosage~~ of 300mg and 720mg respectively.	+	* Aripiprazol Abilify Maintena is a prolonged release suspension for injection and is available in 400mg (once a month) and 960mg (once every two months) preparations. A reduced dose of 75% (300mg and 720mg respectively) can be needed when experiencing side effects.